XTLB XTL Biopharmaceuticals Ltd

VALLEY COTTAGE, N.Y., Oct. 10 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces the results of its Extraordinary General Meetings ("EGMs") held earlier today. The outcome of the EGMs was as follows: all of the resolutions passed and Jennifer L. Good and Kenneth J. Zuerblis were appointed as External Directors of the Company until October 10, 2011. Following the EGMs, XTL's Audit Committee consists of Mr. Zuerblis, Ms. Good and Dr. William Kennedy. With the election of the External Directors by the shareholders and their automatic inclusion in the Audit Committee, XTL has notified NASDAQ that it currently has a valid Audit Committee under the Israeli Companies Act and NASDAQ Marketplace Rule 4350(d)(2). ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a triple reuptake inhibitor of serotonin, norepinephrine and dopamine, which is currently in a Phase 2b study for the treatment of diabetic neuropathic pain. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive Officer, XTL Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225

Copyright